Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: Results of a multicenter, prospective, longitudinal study

Cancer

Volumn 113, Issue 9, 2008, Pages 2431-2439

  Hermelink, Kerstin ^a,d   Henschel, Volkmar ^a   Untch, Michael ^b   Bauerfeind, Ingo ^a   Lux, Michael Patrick ^c   Munzel, Karin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Helios Hospital Berlin Buch   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Adverse effects; Antineoplastic combined chemotherapy protocols; Breast neoplasms; Cognition disorders; Hormone antagonists; Menopause; Neuropsychological tests

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COGNITION; CONTROLLED STUDY; DRUG EFFECT; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; COGNITION; COGNITION DISORDERS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MENOPAUSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 55549083154     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23853     Document Type: Article

References (48)

1. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485-493.
2. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695-2701.
3. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955-969.
4. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640-650.
5. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210-218.
6. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61-66.
7. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-oncology. 2006;15:422-430.
8. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-oncology. 2008;17:122-130.
9. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292-2299.
10. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98:1742-1745.
11. Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog - methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006;95:125-129.
12. Schagen SB, Vardy J. Cognitive dysfunction in people with cancer. Lancet Oncol. 2007;8:852-853.
13. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94: 828-834.
14. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. "Chemobrain" in breast carcinoma? A prologue. Cancer. 2004;101:466-475.
15. Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2007;110:143-152.
16. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007;109:1905-1913.
17. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol. 2007;25:2455-2463.
18. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19:623-629.
19. Hurria A, Somlo G, Ahles T. Renaming "chemobrain." Cancer Invest. 2007;25:373-377.
20. Jenkins V, Atkins L, Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur J Cancer. 2007;43:1342-1347.
21. Gibbs RB. Preclinical data relating to estrogen's effects on cognitive performance. In: Rasgon NL, ed. The Effects of Estrogen on Brain Function. Baltimore, Md: Johns Hopkins University Press; 2006:9-45.
22. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688-695.
23. Brinton RD, Zhao L. Preclinical efforts to develop effective neuro-SERMs for the brain. In: Rasgon NL, ed. The Effects of Estrogen on Brain Function. Baltimore, Md: Johns Hopkins University Press; 2006:116-143.
24. Geerlings MI, Launer LJ, de Jong FH, et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol. 2003;53:607-615.
25. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
26. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291: 2947-2958.
27. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289:2663-2672.
28. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101:485-512.
29. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489-1499.
30. Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94:592-597.
31. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen-and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21:364-371.
32. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165-176.
33. Fan HG, Houede-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year followup of a prospective controlled study. J Clin Oncol. 2005; 23:8025-8032.
34. Fallowfield L. Quality of life issues in relation to the aromatase inhibitor. J Steroid Biochem Mol Biol. 2007;106:168-172.
35. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-oncology. 2004;13:61-66.
36. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14: 995-998.
37. Harting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. WMS-R. Wechsler Gedachtnistest - Revidierte Fassung, 2nd ed. Berne, Switzerland: Verlag Hans Huber; 2004.
38. Tewes U. HAWIE-R. Hamburg-Wechsler Intelligenztest fur Erwachsene, Revision 1991, 2nd ed. Berne, Switzerland: Verlag Hans Huber; 1994.
39. Brickenkamp R. Test d2. Aufmerksamkeits-Belastungs-Test, 9th ed. Gottingen, Germany: Hogrefe Verlag; 2002.
40. Reitan RM. Trail Making Test, 2nd ed. Tucson, Ariz: Reitan Neuropsychology Laboratory; 1992.
41. Aschenbrenner S, Tucha O, Lange KW. RWT. Regensburger Wortflussigkeits-Test. Gottingen, Germany: Hogrefe-Verlag; 2000.
42. Herrmann C, Buss U, Snaith RP. HADS-D. Hospital Anxiety and Depression Scale-German Version. Berne, Switzerland: Verlag Hans Huber; 1995.
43. Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. Balingen, Germany: Spitta Verlag; 1999.
44. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203-214.
45. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment, 4th ed. New York, NY: Oxford University Press; 2004.
46. Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405-412.
47. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143:971-978.
48. Petitti DB, Buckwalter JG, Crooks VC, Chiu V. Prevalence of dementia in users of hormone replacement therapy as defined by prescription data. J Gerontol A Biol Sci Med Sci. 2002;57:M532-M538.